| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 22.13 | -0.15 (-0.67%) | 4.82 - 24.00 | 103.7 thousand |
Market data as of 9:59AM 06/19/13. Quotes are delayed by at least 15 min.
| Open | 22.15 |
|---|---|
| Previous Close | 22.28 |
| Day's Range | 21.91 - 22.26 |
| Market Cap | 1.4B |
| Avg Volume (10 Day) | 998.4K |
| Price/Earnings (Trailing 12 Mo.) | 43.7x |
| Earnings Per Share (Trailing 12 Mo.) | 0.51 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Santarus and Pharming Announce FDA Acceptance for Review of RUCONEST (Recombinant Human C1 Esterase Inhibitor) Biologics License Application
Business Wire - Tuesday 06/18/2013 1:00 AM ET
Santarus President & CEO Gerald Proehl Honored as San Diego Ernst & Young Entrepreneur of the Year 2013 in Life Sciences
Business Wire - Monday 06/17/2013 7:30 AM ET
| SNTS | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 77.31% | |
| Net Income Growth (1yr) | 530.47% | |
| Total Debt/Equity | 0.09 | |
| LT Debt/Equity | 0.09 | |
| Earnings Yield | 2.29% | |
| Price/Sales | 5.75 |
| Company | Last | Change |
|---|---|---|
| Acorda Therapeutics Inc | 35.20 | +0.72% |
| VIVUS Inc | 14.10 | +2.47% |
| Immunogen Inc | 16.49 | +0.67% |
| NPS Pharmaceuticals Inc | 15.23 | -0.65% |
| ACADIA Pharmaceuticals Inc | 18.49 | +0.33% |
Data is delayed by at least 15 min.